TCGA-A7-A4SD-01A-11R-A266-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 15
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- INTERFERON_GAMMA_RESPONSE+0.540
- ALLOGRAFT_REJECTION+0.460
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- MYC_TARGETS_V2+0.350
- WNT_BETA_CATENIN_SIGNALING+0.340
- APICAL_SURFACE+0.330
- E2F_TARGETS+0.320
- MITOTIC_SPINDLE+0.320
Top 10 suppressed
- BILE_ACID_METABOLISM-0.290
- ESTROGEN_RESPONSE_EARLY-0.280
- OXIDATIVE_PHOSPHORYLATION-0.280
- PANCREAS_BETA_CELLS-0.240
- FATTY_ACID_METABOLISM-0.230
- ADIPOGENESIS-0.210
- ESTROGEN_RESPONSE_LATE-0.190
- UV_RESPONSE_DN-0.130
- PEROXISOME-0.120
- HEDGEHOG_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.853 |
| 2 | 20050166.TNBC | — | D | 0.852 |
| 3 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.850 |
| 4 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.843 |
| 5 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.835 |
| 6 | TCGA-92-8064-01A-11R-2247-07 | — | cohortSQ2 | 0.829 |
| 7 | TCGA-77-8136-01A-11R-2247-07 | — | cohortSQ1 | 0.826 |
| 8 | TCGA-E9-A3QA-01A-61R-A22K-07 | — | D | 0.824 |
| 9 | SRR8613750 | — | D | 0.822 |
| 10 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |